Acumen Pharmaceuticals Reports Q3 2026 Financial Results and Awaits Alzheimer's Trial Data
Acumen Pharmaceuticals (ABOS) reported its third-quarter 2026 financial results, highlighting a net loss of $25.4 million, or $0.35 per diluted share. The company holds $78.6 million in cash and marketable securities, which management expects will fund operations into early 2027. Research and development expenses were $21.1 million for the quarter, slightly down from previous periods due to lower manufacturing costs. The market is currently focused on the upcoming topline results from the ALTITUDE-AD Phase 2 clinical trial, expected in November 2026. This study evaluates sabirnetug in 542 participants across several international regions. Additionally, the company is advancing its Enhanced Brain Delivery program with a targeted IND filing for mid-2027.
Tickers: $ABOS
Topics: Alzheimer's disease research cash runway clinical trials financial results
Read the full article at Motley Fool
Part of the story Cincinnati Financial Reports Third-Quarter 2026 Results (18 articles)